alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENTA starts phase-2b trial_of EDP-938 in high-risk adults:
The guys sounds like a bit of a quack.
are you long ABBV? If so why I am curious
I've been buying large pharmas but haven't touched ABBV
Anybody now if there is a reason for the big ABBV decline today? It is down ~$7 or 5%.
Fauci on several televised remarks alluded too that existing vaccines ‘should’ work etc. whenever new variants mushroomed. Needless to say, hardly any of vaccine centers were equipped or advised to do genome testing to see if the vaccine is good for the infected person’s variant.
Those area NOT the latest numbers. The latest data was from Sept of 2021. If you look at the numbers the big deficit increases occurred during the Reagan, Bush, Bush II and tRUMP administrations as I previously stated.
How about we stick to CDMO and its prospects?
Deficit is coming down? Now that's a funny!
Please stop with the politics. I'm happy to discuss economics but don't want to go down in the gutter of politics.
Deficits don't matter when brought about by tax cuts because tax cuts makes the economy grow eliminating the deficit.
Deficits do matter when brought about by over spending because over spending causes inflation and only way to decrease inflationary pressures is to shrink the economy.
I sure hope ENTA announces their phase 2 or phase 2/3 EDP-235 trial soon. I wouldn’t mind hearing that a new HBV inhibitor has been selected either.
The gross proceeds of the offering are now $230M, and the net proceeds (after the underwriters’ fee) are approximately $216M, as stated in the post I’m replying to.
I was able to buy more CDMO at $18. I also added SGEN and LGND.
What rolling blackouts?
Roller coasters are far more enjoyable than riding on a carousel!
Hence, on today's CC RVNC said to expect relatively modest sales in 4Q22 and 1Q23 followed by a big jump in 2Q23.
EDP-235 as possible treatment for long COVID?
A Key to Long Covid Is Virus Lingering in the Body, Scientists Say
Virus remaining in some people’s bodies for a long time may be causing longer-term complications, recent research suggests
RVNC for those of us too busy or lazy to read the label anything of note especially on duration?
Dew, that sounds like a really tough road you have been on. Glad to you are improving and hope the improvement continues. Take care.
djohn,
I added more at $16.19 so wish to thank those who did some panic selling for driving the CDMO stock price down and giving me a bargain. Also put in an order for SGEN at $152.30.
Why not a feeling of 'encouraging' for those of us that have declined all covid vaccines and doing well without any!
If you sold your NVAX a month ago and only bought back 10% of your position, you know something.
willyw,
Thanks for that excellent post.
With decision day looming, I cant help but reflect on what a covered call option seller's dream this has been over the last 3+ years.
I got my second booster in mid-April. I will probably wait a few more months so I can get the hybrid vaccine before the holidays.
Update on Pfizer's aquisition of Trillium and other cd47 competitors
ENTA had ~$330M of pro forma cash at 6/30/22 (#msg-169621212), so the ATM looks like a backup contingency in case ENTA decides to conduct the phase-2(/3) EDP-235 trial without a partner.
There are two ways of looking at this from ENTA’s perspective. The bearish take is that COVID antivirals aren’t needed in adults under age 65 lacking major risk factors, limiting the addressable market for EDP-235. The bullish viewpoint is that Paxlovid isn’t potent enough to help low-risk patients, but a superior drug such as EDP-235 could find an opening where Paxlovid has been shown to be ineffective.
The market seems to agree with the bearish take, as least for today.
There are two ways of looking at this from ENTA’s perspective. The bearish take is that COVID antivirals aren’t needed in adults under age 65 lacking major risk factors, limiting the addressable market for EDP-235.
If you sold your NVAX a month ago and only bought back 10% of your position, you know something.
Hope you didn’t sell pre-market:).
Best of luck on what ever choice you make!
I am feeling less confident than many here. I am thinking of selling some shares, at some 25% profit.
It looks like shares are back on sale....do you feel lucky!?
It looks like a broad based downturn in biotech today. I wouldn’t be surprised if it were a fallout from the massive NVAX drop. I am going to use it to pick up some bargains.
It looks like a broad based downturn in biotech today. I wouldn’t be surprised if it were a fallout from the massive NVAX drop. I am going to use it to pick up some bargains.
Shorts covering their positions would typically cause the stock to go up, not down.
Before moving to the financials, I want to address briefly our ongoing patent litigation in which we are seeking damages for Pfizer's infringement of our issued 953 patent in the manufacture, use and sale of its COVID-19 antiviral paxlobid.
We recognize the importance of paxlovid's availability for patients and we do not intend to seek an injunction or take other action in this litigation to impede the production, sale or distribution of paxlovid. And finally, in this lawsuit, we are taking steps to ensure that we will be fairly compensated for our intellectual property. Importantly, our 953 patent is completely separate from the patent estate covering our discovery of EDP-235 and our ongoing antiviral discovery work for coronaviruses. Indeed, we have a growing 3CL protease inhibitor patent estate, including several issued U.S. patents, one of which covers EDP-235. These patents describe compounds built on an independent and distinct chemical scaffold from the one described in the 953 patent and in Pfizer's patents for paxlovid.
Before moving to the financials, I want to address briefly our ongoing patent litigation in which we are seeking damages for Pfizer's infringement of our issued 953 patent in the manufacture, use and sale of its COVID-19 antiviral paxlobid.
We recognize the importance of paxlovid's availability for patients and we do not intend to seek an injunction or take other action in this litigation to impede the production, sale or distribution of paxlovid. And finally, in this lawsuit, we are taking steps to ensure that we will be fairly compensated for our intellectual property. Importantly, our 953 patent is completely separate from the patent estate covering our discovery of EDP-235 and our ongoing antiviral discovery work for coronaviruses. Indeed, we have a growing 3CL protease inhibitor patent estate, including several issued U.S. patents, one of which covers EDP-235. These patents describe compounds built on an independent and distinct chemical scaffold from the one described in the 953 patent and in Pfizer's patents for paxlovid.
ENTA might be able to commercialize without a partner in RSV, but I doubt they would attempt to do so in HBV, where a large proportion of the addressable market is ex-US.
ENTA hires CMO with Big Pharma credentials:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-appoints-scott-t-rottinghaus-md-senior
So do we know for certain that the MOA of ENTAs drug identical?